Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > routes: Oral

& pregnancy

: Category C

or Limited data; avoid

Use the filters below to narrow your results.

None (5) · Bisoprolol (1) · Dexmethylphenidate (1) · Duloxetine (1) · Haloperidol (1) · Metoprolol (1) · Mixed amphetamine salts (1) · Nebivolol (1) · Prazosin (1) · Propranolol (1)

Adderall, Adderall XR, Mydayis (1) · Auvelity (dextromethorphan/bupropion ER) (1) · Belsomra (1) · Bystolic (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dayvigo (1) · Focalin, Focalin XR (1) · Haldol, Serenace, Haldol Decanoate (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Minipress (1) · Nuplazid (1) · Quviviq (1) · Zebeta (1)

Alpha-1 Adrenergic Antagonist (1) · Amphetamine (1) · Antidepressant (1) · Antiemetic (1) · Anxiolytic (1) · Beta Blocker (4) · Cardioselective (β1) (2) · Cardioselective (β1) + vasodilator (1) · CNS stimulant (1) · Dual orexin receptor antagonist (DORA) (3) · NDRI (1) · NMDA receptor antagonist + sigma-1 agonist + NDRI (combination) (1) · Non-selective (1) · Psychostimulant (2) · Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) (1) · SNRI (1) · the first approved (1) · Typical antipsychotic (1)

None (2) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · High-affinity D2 receptor antagonist (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)

Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · Major depressive disorder in adults (FDA-approved August 2022) (1) · Schizophrenia, acute psychosis, agitation, delirium, Tourette syndrome, severe nausea (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1) · '"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1)

None (3) · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) · 1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 34 mg PO once daily (1) · 5 mg daily (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1)

None (3) · 1, 2, 5 mg caps (1) · 10 mg, 34 mg capsules/tablets (1) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 25 mg, 50 mg tablets (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · 5, 10 mg tabs (1) · Dextromethorphan 45 mg + bupropion 105 mg ER tablets (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (3) · 10 mg/d (1) · 2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg) (1) · 20 mg/d (2) · 34 mg/d (1) · 40 mg/d (2) · 400 mg/d (1) · 50 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 30–60 min (1) · 30–90 min (1) · Benefit over weeks of dosing (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PO 1–2 h; IM 30–60 min; IV 5–20 min (1) · Significant antidepressant response by week 1 in trials (faster than monoaminergic antidepressants which take 4-6 weeks) (1) · ~30 min (3)

12–24 h (oral); decanoate IM 3–4 weeks (1) · 24 h (2) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · 6–8 h (1) · Chronic daily dosing (1) · Daily dosing (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1) · Sustained with twice-daily dosing (1) · ~7-8 hours (3)

14–26 h (oral); ~3 weeks (decanoate) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (1) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~12 hours (2) · ~17-19 hours (longer than daridorexant) (1) · ~57 hours (parent), ~200 h (active metabolite) (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

Not characterized; oral dosing once daily (1) · Not formally characterized for the combination (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~22–25% (1) · ~25% (extensive hepatic first-pass) (1) · ~44% (1) · ~50% (1) · ~50% (highly variable) (1) · ~60% (1) · ~60–70% (oral) (1) · ~62% (1) · ~75–90% (oral) (1) · ~82% (1) · ~90% (low first-pass) (1)

Rx (1) · Rx, Schedule IV (US) (3) · Rx-only (2) · Rx-only in US (5) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · Schedule II (2)

Showing below up to 14 results in range #1 to #14.

A

Auvelity

B

Bisoprolol

D

H

Haloperidol

L

Lemborexant

M

N

Nebivolol

P

S

Suvorexant

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"